Portal de Periódicos da CAPES

Nephrotic Range of Proteinuria and Interferon Therapy

1992; American College of Physicians; Volume: 116; Issue: 4 Linguagem: Inglês

10.7326/0003-4819-116-4-347_1

1539-3704

Kenneth S. Weiss,

Mast cells and histamine

Letters15 February 1992Nephrotic Range of Proteinuria and Interferon TherapyKenneth S. Weiss, MDKenneth S. Weiss, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-4-347_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Nephrotic range proteinuria is a well-documented side effect of recombinant gamma interferon and all other interferons (1-3). The doses reported to cause this effect have been in the range of 0.25 mg/m2 to 1 mg/m2 body surface area (activity, 1 x 107 units per milligram of protein). I report a case of nephrotic-range proteinuria in a patient receiving therapy at a much lower dose.A 64-year-old man had wide excision and skin grafting for a Clark level-IV (11.2 mm-thick) malignant melanoma on his midback. He soon thereafter developed axillary adenopathy, consistent with metastatic melanoma. He agreed to...References1. BennettVogelzangRatain CNM. Severe toxicity (r-Ifn gamma) phase I trial of vinblastine (VLB) and recombinant gamma-interferon. Proc ASCO. 1986;5:223. Google Scholar2. SriskandianGarnerWatkinson KDJ. A toxicity study of recombinant interferon gamma given by intravenous infusion to patients with advanced cancer. Cancer Chemother Pharmacol. 1986;18:63-8. CrossrefMedlineGoogle Scholar3. GarnickReichRichie MSJ. Phase I/II study of interferon gamma (Immuneron) in advanced renal cell carcinoma (RCC) [Abstract]. J Urol. 1986;135:166A. Google Scholar4. SelbyKohnRaymond PJJ. Nephrotic syndrome during treatment with interferon [Letter]. Br J Med. 1985;290:1180. CrossrefMedlineGoogle Scholar5. SriskandianTeePettingale KDK. Nephrotic syndrome during treatment with interferon. Br Med J. 1985;290:1590-1. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Kaiser Permanente Medical Center Cleveland, OH 44130 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMedication-Associated Glomerular DiseaseMedication-Associated Glomerular DiseaseVascularite cutanée avec atteinte rénale compliquant un traitement par interféron bêta-1a pour une sclérose en plaquesNephrotoxicity of Interferon Alfa–Ribavirin Therapy for Chronic Hepatitis CINTERFERON-?? TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemiaInterferon-gamma (IFN-γ) and IL-4 expressed during mercury-induced membranous nephropathy are toxic for cultured podocytesNéphropathies secondaires aux interférons alpha: à propos de deux observationsMaladies auto-immunes et traitement par l'IFN-α: revue de la littérature à propos d'un cas d'hyperthyroïdieAntiviral drugsInterferon gamma 15 February 1992Volume 116, Issue 4Page: 347-347KeywordsBody surface areaInterferonsMelanomaMembrane proteinsProteinuriaSkin grafting Issue Published: 15 February 1992 PDF downloadLoading ...